Abstract
Ruxolitinib cream has been approved by the United States Food and Drug Administration for the treatment of mild to moderate atopic dermatitis (AD). Ruxolitinib is an inhibitor of Janus family of protein tyrosine kinases (JAK) 1 and 2. Two randomized, vehicle-controlled phase 3 studies with identical design were conducted in adolescent and adult patients with up to 20% body surface area (BSA) affected by AD (TRuE-AD1 and TRuE-AD2). Serum samples for biomarker analysis were collected from all patients at baseline and week 8.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
